Treatment of attention deficit hyperactivity disorder in children: Assessment of moclobemide a non-psichostimulant alternative;Tratamiento del síndrome de déficit atencional (SDA) en niños: Evaluación de la moclobemida, una alternativa no psicoestimulante

Revista Chilena de Neuro-Psiquiatria

Volumn 38, Issue 1, 2000, Pages 7-14

  Valdivieso, Alicia ^a,d   Cornejo, Andrea ^b   Sánchez, Matías ^c  

^a HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^b UNIVERSIDAD DIEGO PORTALES   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

^d NONE   (Chile)

Author keywords

ADHD diagnosis; Antidepressants; Attention Deficit Hyperactivity Disorder (ADHD); Drug therapy; Methylphenidate, D amphetamine, pemoline; Moclobemide; Psychostimulants

Indexed keywords

ANTIDEPRESSANT AGENT; MOCLOBEMIDE;

ADOLESCENT; ANAMNESIS; APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD CELL COUNT; CARDIOVASCULAR SYMPTOM; CHILD; CLINICAL TRIAL; COLD SENSATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; HUMAN; IMMATURITY; MALE; MEDICAL EXAMINATION; NEUROLOGIC EXAMINATION; PSYCHOLOGIC TEST; SCORING SYSTEM; SIDE EFFECT; SYMPTOM; TEACHER; VITAL SIGN;

EID: 31644448019     PISSN: 00347388     EISSN: 07179227     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Weiss G (editores). Child and Adolescent Psychiatry. A Comprehensive Textbook. Baltimore, London, Tokyo: Editorial Williams & Wilkins, 1991
2. Barkley A (editores). Attention Deficit Hyperactivity Disorder, A Handbook for Diagnosis and Treatment. New York, London: Editorial Guilford Press, 1990
3. Pichot P, López-Igor J (editores). DSM-IV: Manual Diagnóstico y Estadístico de los Trastornos Mentales. Barcelona: Editorial Masson, 1995
4. Sleator E, Ullman R. Can the physician diagnose hyperactivity in the office? Pediatrics 1981; 67: 13-7
5. Swanson JM, Sergeant JA, Taylor E, Sonuga-Barke EJ, Jensen PS, Cantwell DP. Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 1998; 351: 429-33.
6. Comment in: Lancet 1998; 351: 387
7. Cantwell DP, Baker L. Attention deficit disorder with and without hyperactivity: a review and comparison of matched groups. J Am Acad Child Adolesc Psychiatry 1992; 31: 432-8
8. Barkley RA, DuPaul GJ, McMurray MB. Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate. Pediatrics 1991; 87: 519-31
9. Borcherding BG, Keysor CS, Cooper TB, Rapoport JL. Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children. Neuropsychopharmacology 1989; 2: 255-63
10. Collier CP, Soldin SJ, Swanson JM, MacLeod SM, Weinberg F, Rochefort JG. Pemoline pharmacokinetics and long term therapy in children with attention deficit disorder and hyperactivity. Clin Pharmacokinet 1985; 10: 269-78
11. Conners CK, Taylor E. Pemoline, methylphenidate, and placebo in children with minimal brain dysfunction. Arch Gen Psychiatry 1980; 37: 922-30
12. Smith BH et al. Dosage effects of methylphenidate on the social behavior of adolescents diagnosed with attention-deficit hyperactivity disorder. Exp Clin Psychopharmacol 1998; 2: 187-204
13. Costall B, Naylor RJ. The involvement of dopaminergic systems with the stereotyped behavior patterns induced by methylphenidate. J Pharm Pharmacol 1974; 26: 30-3
14. Pliszka SR. The use of psychostimulants in the pediatric patient. Pediatric Clinic North Am 1998; 45: 1085-98
15. Popper CW. Antidepressants in the treatment of attention-deficit- hyperactivity disorder. J Clin Psychiatry 1997; 58(Suppl 14): 14-29
16. Silva M (editor). Monografía Metilfenidato. Anuario Farmacológico de Chile. Antártica Quebecor SA, 1999; 1134
17. Marotta PJ, Roberts EA. Pemoline hepatotoxicidad in children. J Pediatr 1998; 132: 894-7
18. Valdivieso A. Resumen presentación. Evaluación preliminar de la moclobemida en Síndrome de Déficit Atencional. Congreso Neurología Infantil, 1997
19. Zametkin A, Ernst M. Problems in the management of Attention-Deficit- Hyperactivity Disorder. New England J Med 1990; 340: 40-6
20. Levin FR. Attention-deficit hyperactivity disorder and substance abuse-relationship and implications for treatment. Harvard: Rev Psychiatry 1995; 2: 246-58
21. Wilens TE, Biederman J, Mick E, Faraone SV, Spencer T. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis 1997; 185: 475-82
22. Pliszka SR. Tricyclic antidepressants in the treatment of children with Attentional Deficit Disorder. J Am Acad Child Adolesc Psychiatry 1987; 26: 127-32
23. Roth M, Mountjoy CQ, Amrein R. Moclobemide in elderly patients with cognitive decline and depression. British J Psychiatry 1996; 168: 149-57
24. Trott GE, Friese HJ, Mensel M, Nissen G. Use of moclobemide in children with attention deficit hyperactivity disorder. Psychopharmacology 1992; 106: S134-S36
25. Behaviour rating scales, Chap 9. Attention Deficit Hyperactivity Disorder, A Handbook for Diagnosis and Treatment. Russell A Barkley ed. The Guilford Press 1990; 278-314. Conners Parent Rating Scale-Revised (CPRS, C. Keith Conners, 1978)
26. Conners CK. Rating scales in attention-deficit/ hyperactivity disorder: use in assessment and treatment monitoring. J Clin Psychiatry 1998; 59: 24-30
27. Stanley D. Porteus A (editores). Porteus Maze Test: Fifty Year's Application. California: Editorial Pacific PB Books, 1965
28. Kagan J. Reflection-impulsivity: the generality and dynamics of conceptual tempo. J Abnorm Psychol 1966; 71: 17-24
29. Cyr M, Brown CS. Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder. Drugs 1998; 56: 215-23
30. Sagvolden T, Sergeant JA. Attention deficit/hyperactivity disorder from brain dysfunction to behaviour. Behav Brain Res 1998; 94: 1-10
31. Swanson JM, Sergeant JA, Taylor E, SonugaBarke EJS, Jensen PS, Cantwell DP. Attentiondeficit hyperactivity disorder and hyperkinetic disorder. Lancet 1998; 351: 429-33
32. Garland EJ. Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats. J Psychopharmacol 1998; 12: 385-95
33. Daly JM, Wilens T. The use of tricyclic antidepressants in children and adolescents. Pediatr Clin North Am 1998; 45: 1123-35
34. Wesnes KA, Simpson PM, Christmas L, McClelland GR, Joiner IM. Acute cognitive effects of moclobemide and trazodone alone and in combination with alcohol in the elderly. Br J Clin Pharmacology 1989b; 27: 647P-48P
35. Roth M, Mountjoy CQ, Amrein M. Moclobemide in elderly patients with cognitive decline and depression. Br J Psychiatry 1996; 168: 149-57
36. Versiani M, Nardi A, Figueira ILV, Stabl M. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A compared with other antidepressants and placebo. Acta Psychiatrica Scandinavica 1990; 82(Suppl 360): 24-8
37. Fulton B, Benfield P. Moclobemide: An update of its pharmacological properties and therapeutic use. Drugs 1996; 52: 450-74
38. Fitton A, Faulds D, Goa KL. Moclobemide a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992; 43: 561-96